Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Novo Nordisk A/S(NVO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NVO
10/26/2026: NVO (1-star) is currently NOT-A-BUY. Pass it for now.
Novo Nordisk A/S is a global leader in metabolic disease treatments, particularly recognized for its strong position in diabetes and obesity care. The stock is best suited for growth-oriented investors who are comfortable with sector-specific risks, as its recent performance is closely tied to the global commercial success of its GLP-1 products. While the company maintains a stable financial profile and has an established R&D engine, primary risks include intensifying competition from rivals and potential manufacturing bottlenecks. Prospective investors should monitor clinical trial results, supply chain expansion progress, and evolving healthcare pricing regulations to assess its ongoing potential to maintain its market position.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company's focus on high-growth metabolic therapies aligns well with growth-oriented investment mandates. |
| Momentum investor | Strong fit while signal remains positive | Strong momentum has been supported by the structural growth in the GLP-1 market class. |
| Value investor | Mixed fit | Market enthusiasm often leads to premium valuation multiples, which may challenge pure value investors. |
| Dividend investor | Mixed fit | While dividends are paid, the primary driver for total return has been capital appreciation rather than yield. |
| Low-risk investor | Mixed fit | While the business is high quality, the stock can experience volatility due to healthcare sector dynamics and high expectations. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock's valuation is sensitive to news regarding clinical trials and supply updates. |
| Valuation risk | Medium / high | High growth expectations are priced in, leaving little room for earnings disappointments. |
| Competition risk (GLP-1 rivalry) | High | Aggressive competition from Eli Lilly threatens market share and pricing power. |
| Business quality | Strong | The company benefits from a deep-moat position in its core clinical therapeutic areas. |
| Dividend income | Low | Dividends are reliable but not the primary focus for total returns compared to growth. |
| Execution risk | Medium / high | The ability to scale manufacturing to meet global demand is critical for future performance. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 8.52% | Avg. Invested days 62 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/26/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 172.28B USD | Price to earnings Ratio 9.19 | 1Y Target Price 45.14 |
Price to earnings Ratio 9.19 | 1Y Target Price 45.14 | ||
Volume (30-day avg) 13.4M shares | Beta 0.38 | 52 Weeks Range 34.15 - 61.11 | Updated Date 10/25/2026 |
52 Weeks Range 34.15 - 61.11 | Updated Date 10/25/2026 | ||
Dividends yield (FY) 4.60% | Basic EPS (TTM) 4.25 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diabetes Care | GLP-1s, insulin, and related delivery devices. | This is the primary legacy revenue engine that provides stable cash flows. |
| Obesity Care | Semaglutide products like Wegovy. | This is the primary growth engine driving recent investor interest. |
| Geography: North America | Sales across the US and Canada. | This region typically contributes the largest share of revenue and profit. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 9.19 | Forward PE 14.08 | Enterprise Value 271.80B | Price to Sales(TTM) 0.52 |
Enterprise Value 271.80B | Price to Sales(TTM) 0.52 | ||
Enterprise Value to Revenue 5.54 | Enterprise Value to EBITDA 11.2 | Shares Outstanding 3.34B | Shares Floating 3.17B |
Shares Outstanding 3.34B | Shares Floating 3.17B | ||
Percent Insiders - | Percent Institutions 9.82 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.